JP2011515396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515396A5 JP2011515396A5 JP2011500799A JP2011500799A JP2011515396A5 JP 2011515396 A5 JP2011515396 A5 JP 2011515396A5 JP 2011500799 A JP2011500799 A JP 2011500799A JP 2011500799 A JP2011500799 A JP 2011500799A JP 2011515396 A5 JP2011515396 A5 JP 2011515396A5
- Authority
- JP
- Japan
- Prior art keywords
- fluorophenyl
- methyl
- carboxy
- phenyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-carboxyethylamino, 1-carboxy-4-guanidinobutylamino, 3-amino- 1-carboxy-3-oxopropylamino, 1,2-dicarboxyethylamino, 1-carboxy-2-mercaptoethylamino, 4-amino-1-carboxy-4-oxobutylamino Chemical group 0.000 claims description 1374
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 594
- 150000001875 compounds Chemical class 0.000 claims description 536
- 150000003839 salts Chemical class 0.000 claims description 276
- 239000012453 solvate Substances 0.000 claims description 276
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 236
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 232
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 232
- 238000011282 treatment Methods 0.000 claims description 225
- 125000003118 aryl group Chemical group 0.000 claims description 223
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 167
- 125000001072 heteroaryl group Chemical group 0.000 claims description 128
- 229910052799 carbon Inorganic materials 0.000 claims description 107
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 106
- 229910052739 hydrogen Inorganic materials 0.000 claims description 105
- 239000003814 drug Substances 0.000 claims description 104
- 239000008194 pharmaceutical composition Substances 0.000 claims description 96
- 125000001424 substituent group Chemical group 0.000 claims description 96
- 238000004519 manufacturing process Methods 0.000 claims description 91
- 150000004677 hydrates Chemical class 0.000 claims description 90
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 88
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 86
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 81
- 229910052736 halogen Inorganic materials 0.000 claims description 77
- 150000002367 halogens Chemical class 0.000 claims description 77
- 239000000126 substance Substances 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 71
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 62
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 61
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 56
- 102000009079 Epoprostenol Receptors Human genes 0.000 claims description 49
- 108010073099 Epoprostenol Receptors Proteins 0.000 claims description 49
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 45
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 44
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 44
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 44
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 44
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 44
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 44
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 44
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 44
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 44
- 208000035475 disorder Diseases 0.000 claims description 42
- 208000006673 asthma Diseases 0.000 claims description 34
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims description 31
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 31
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims description 30
- 201000001320 Atherosclerosis Diseases 0.000 claims description 29
- 206010063837 Reperfusion injury Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 29
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 29
- 208000035478 Interatrial communication Diseases 0.000 claims description 28
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 claims description 28
- 208000013914 atrial heart septal defect Diseases 0.000 claims description 28
- 206010003664 atrial septal defect Diseases 0.000 claims description 28
- 208000037803 restenosis Diseases 0.000 claims description 28
- 201000003130 ventricular septal defect Diseases 0.000 claims description 28
- DVMILACIDBEACH-UHFFFAOYSA-N 6-fluoropyridine Chemical compound FC1=C=CC=C[N]1 DVMILACIDBEACH-UHFFFAOYSA-N 0.000 claims description 26
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 25
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 22
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 22
- 206010020772 Hypertension Diseases 0.000 claims description 22
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 22
- 230000035602 clotting Effects 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 20
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 19
- 206010040047 Sepsis Diseases 0.000 claims description 19
- 208000021076 Pulmonary arterial hypertension associated with congenital heart disease Diseases 0.000 claims description 18
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 17
- 238000002411 thermogravimetry Methods 0.000 claims description 17
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 15
- 206010002383 Angina Pectoris Diseases 0.000 claims description 15
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 15
- 208000011231 Crohn disease Diseases 0.000 claims description 15
- 208000031886 HIV Infections Diseases 0.000 claims description 15
- 208000037357 HIV infectious disease Diseases 0.000 claims description 15
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims description 15
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 208000019693 Lung disease Diseases 0.000 claims description 15
- 208000006011 Stroke Diseases 0.000 claims description 15
- 206010052779 Transplant rejections Diseases 0.000 claims description 15
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 15
- 230000002159 abnormal effect Effects 0.000 claims description 15
- 206010000496 acne Diseases 0.000 claims description 15
- 230000007214 atherothrombosis Effects 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 15
- 208000029078 coronary artery disease Diseases 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 15
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 230000004410 intraocular pressure Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 208000010125 myocardial infarction Diseases 0.000 claims description 15
- 230000000414 obstructive effect Effects 0.000 claims description 15
- 238000010911 splenectomy Methods 0.000 claims description 15
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 15
- 239000003053 toxin Substances 0.000 claims description 15
- 231100000765 toxin Toxicity 0.000 claims description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 15
- 201000002829 CREST Syndrome Diseases 0.000 claims description 14
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 14
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 14
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 14
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 14
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 14
- 206010039710 Scleroderma Diseases 0.000 claims description 14
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 14
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 14
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 14
- 201000006417 multiple sclerosis Diseases 0.000 claims description 14
- 208000003278 patent ductus arteriosus Diseases 0.000 claims description 14
- 208000005987 polymyositis Diseases 0.000 claims description 14
- 210000003492 pulmonary vein Anatomy 0.000 claims description 14
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 13
- 208000021068 Pulmonary arterial hypertension associated with portal hypertension Diseases 0.000 claims description 13
- 208000030533 eye disease Diseases 0.000 claims description 13
- 201000001981 dermatomyositis Diseases 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 230000001052 transient effect Effects 0.000 claims description 11
- 230000002490 cerebral effect Effects 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 230000000302 ischemic effect Effects 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 206010012667 Diabetic glaucoma Diseases 0.000 claims description 7
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000003944 tolyl group Chemical group 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000004892 2-methylpropylamino group Chemical group CC(CN*)C 0.000 claims description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 4
- NPDKXVKJRHPDQT-UHFFFAOYSA-N 2-[[4-[[(4-chlorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 NPDKXVKJRHPDQT-UHFFFAOYSA-N 0.000 claims description 3
- XCIVGPGSJPAWCB-UHFFFAOYSA-N 2-[[4-[[(4-fluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=CC(F)=CC=1)C1=CC=CC=C1 XCIVGPGSJPAWCB-UHFFFAOYSA-N 0.000 claims description 3
- CMXRZQLTIHQYPZ-UHFFFAOYSA-N 2-[[4-[[[(3-chlorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(Cl)C=CC=1)C1=CC=CC=C1 CMXRZQLTIHQYPZ-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- BXMBDSIYGOKPJM-UHFFFAOYSA-L C(C)(C)O.C(C)(=O)[O-].[Ca+2].C(C)(=O)[O-] Chemical compound C(C)(C)O.C(C)(=O)[O-].[Ca+2].C(C)(=O)[O-] BXMBDSIYGOKPJM-UHFFFAOYSA-L 0.000 claims description 2
- XGULNLBDYZNHDJ-UHFFFAOYSA-L C(C)(C)O.C(C)(=O)[O-].[Mg+2].C(C)(=O)[O-] Chemical compound C(C)(C)O.C(C)(=O)[O-].[Mg+2].C(C)(=O)[O-] XGULNLBDYZNHDJ-UHFFFAOYSA-L 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 208000020193 Pulmonary artery hypoplasia Diseases 0.000 claims 22
- JPQUDQIQRLMROB-UHFFFAOYSA-N [K].CC(C)O Chemical compound [K].CC(C)O JPQUDQIQRLMROB-UHFFFAOYSA-N 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 175
- 239000013078 crystal Substances 0.000 description 23
- 229940126208 compound 22 Drugs 0.000 description 17
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 16
- 125000001188 haloalkyl group Chemical group 0.000 description 16
- 108700012359 toxins Proteins 0.000 description 13
- 150000001408 amides Chemical class 0.000 description 12
- 208000027866 inflammatory disease Diseases 0.000 description 12
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 9
- 208000010412 Glaucoma Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229940125833 compound 23 Drugs 0.000 description 9
- 229960001123 epoprostenol Drugs 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- 238000002399 angioplasty Methods 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 150000001934 cyclohexanes Chemical class 0.000 description 6
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 125000003636 chemical group Chemical group 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 125000004663 dialkyl amino group Chemical group 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229910052703 rhodium Inorganic materials 0.000 description 4
- 239000010948 rhodium Substances 0.000 description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 4
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- JBVSBLLOZVDAAZ-UHFFFAOYSA-N 2-diazonio-1-[(2-methylpropan-2-yl)oxy]ethenolate Chemical compound CC(C)(C)OC([O-])=C[N+]#N JBVSBLLOZVDAAZ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000003815 prostacyclins Chemical class 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PRRDEJJYDQAWMQ-UHFFFAOYSA-N 2-[[4-(aminomethyl)cyclohexyl]methoxy]acetic acid Chemical compound NCC1CCC(COCC(O)=O)CC1 PRRDEJJYDQAWMQ-UHFFFAOYSA-N 0.000 description 2
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 2
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JSRMGTKGAVBPKL-UHFFFAOYSA-N tert-butyl 2-[[4-(aminomethyl)cyclohexyl]methoxy]acetate Chemical compound CC(C)(C)OC(=O)COCC1CCC(CN)CC1 JSRMGTKGAVBPKL-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- GDJMTGQHKNDISN-UHFFFAOYSA-N 2-[[4-(diphenylcarbamoyloxymethyl)cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 GDJMTGQHKNDISN-UHFFFAOYSA-N 0.000 description 1
- GUTKNPKVCGDVLI-UHFFFAOYSA-N 2-[[4-(phenylcarbamoyloxymethyl)cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)NC1=CC=CC=C1 GUTKNPKVCGDVLI-UHFFFAOYSA-N 0.000 description 1
- XOVSMYQHSGFUMW-UHFFFAOYSA-N 2-[[4-[(benzhydrylcarbamoylamino)methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 XOVSMYQHSGFUMW-UHFFFAOYSA-N 0.000 description 1
- FMSPYCIOLLLRCM-UHFFFAOYSA-N 2-[[4-[(diphenylcarbamoylamino)methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 FMSPYCIOLLLRCM-UHFFFAOYSA-N 0.000 description 1
- PZXYMNWVNRTHKN-UHFFFAOYSA-N 2-[[4-[[(2,3-difluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C(=C(F)C=CC=1)F)C1=CC=CC=C1 PZXYMNWVNRTHKN-UHFFFAOYSA-N 0.000 description 1
- JJNKTKDAONRNHI-UHFFFAOYSA-N 2-[[4-[[(2-methoxyphenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound COC1=CC=CC=C1N(C=1C=CC=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 JJNKTKDAONRNHI-UHFFFAOYSA-N 0.000 description 1
- TYTOIJSJGRLOHO-UHFFFAOYSA-N 2-[[4-[[(3,4-difluorophenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C(F)=CC=1)C1=CC=CC(F)=C1 TYTOIJSJGRLOHO-UHFFFAOYSA-N 0.000 description 1
- KDHKZSVRIRHRKL-UHFFFAOYSA-N 2-[[4-[[(3,4-difluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C(F)=CC=1)C1=CC=CC=C1 KDHKZSVRIRHRKL-UHFFFAOYSA-N 0.000 description 1
- WNCURKKMOWIQIB-UHFFFAOYSA-N 2-[[4-[[(3,5-difluorophenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=C(F)C=1)C1=CC=CC(F)=C1 WNCURKKMOWIQIB-UHFFFAOYSA-N 0.000 description 1
- QIAJRZFLAJESHJ-UHFFFAOYSA-N 2-[[4-[[(3,5-difluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=C(F)C=1)C1=CC=CC=C1 QIAJRZFLAJESHJ-UHFFFAOYSA-N 0.000 description 1
- ICLJHNYLLJGNAO-UHFFFAOYSA-N 2-[[4-[[(3,5-dimethylphenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound CC1=CC(C)=CC(N(C(=O)OCC2CCC(COCC(O)=O)CC2)C=2C=C(F)C=CC=2)=C1 ICLJHNYLLJGNAO-UHFFFAOYSA-N 0.000 description 1
- WYEWJQSVTXFZRZ-UHFFFAOYSA-N 2-[[4-[[(3-chloro-4-fluorophenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(Cl)C(F)=CC=1)C1=CC=CC(F)=C1 WYEWJQSVTXFZRZ-UHFFFAOYSA-N 0.000 description 1
- NRKJNRVVXRLPRD-UHFFFAOYSA-N 2-[[4-[[(3-chloro-4-fluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(Cl)C(F)=CC=1)C1=CC=CC=C1 NRKJNRVVXRLPRD-UHFFFAOYSA-N 0.000 description 1
- LNLGYZUVANMNCR-UHFFFAOYSA-N 2-[[4-[[(3-chloro-5-fluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(Cl)C=C(F)C=1)C1=CC=CC=C1 LNLGYZUVANMNCR-UHFFFAOYSA-N 0.000 description 1
- KHYMCFSWUIRROR-UHFFFAOYSA-N 2-[[4-[[(3-chlorophenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(Cl)C=CC=1)C1=CC=CC(F)=C1 KHYMCFSWUIRROR-UHFFFAOYSA-N 0.000 description 1
- RLGMKALPMCEYMH-UHFFFAOYSA-N 2-[[4-[[(3-chlorophenyl)-(4-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(Cl)C=CC=1)C1=CC=C(F)C=C1 RLGMKALPMCEYMH-UHFFFAOYSA-N 0.000 description 1
- DNBJSWUQGXMSOJ-UHFFFAOYSA-N 2-[[4-[[(3-chlorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(Cl)C=CC=1)C1=CC=CC=C1 DNBJSWUQGXMSOJ-UHFFFAOYSA-N 0.000 description 1
- ZQIOCOALFDLMKE-UHFFFAOYSA-N 2-[[4-[[(3-fluoro-4-methylphenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=C(F)C(C)=CC=C1N(C=1C=C(F)C=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 ZQIOCOALFDLMKE-UHFFFAOYSA-N 0.000 description 1
- SIOXTSSIUJKEAD-UHFFFAOYSA-N 2-[[4-[[(3-fluoro-4-methylphenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=C(F)C(C)=CC=C1N(C=1C=CC=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 SIOXTSSIUJKEAD-UHFFFAOYSA-N 0.000 description 1
- XNVRPYIZWKXXTL-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(3-methoxyphenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound COC1=CC=CC(N(C(=O)OCC2CCC(COCC(O)=O)CC2)C=2C=C(F)C=CC=2)=C1 XNVRPYIZWKXXTL-UHFFFAOYSA-N 0.000 description 1
- JLIKIUGJKYAFKT-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(3-methylphenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound CC1=CC=CC(N(C(=O)OCC2CCC(COCC(O)=O)CC2)C=2C=C(F)C=CC=2)=C1 JLIKIUGJKYAFKT-UHFFFAOYSA-N 0.000 description 1
- KOMJQCSEFACZRE-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(4-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=CC=1)C1=CC=C(F)C=C1 KOMJQCSEFACZRE-UHFFFAOYSA-N 0.000 description 1
- ODBRGXOTFQMPQS-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(4-methoxyphenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N(C=1C=C(F)C=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 ODBRGXOTFQMPQS-UHFFFAOYSA-N 0.000 description 1
- WWKMUZSOBDQEHP-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(4-methylphenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(C)=CC=C1N(C=1C=C(F)C=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 WWKMUZSOBDQEHP-UHFFFAOYSA-N 0.000 description 1
- ONIWPUAJNWCHCD-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(5-methylthiophen-2-yl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound S1C(C)=CC=C1N(C=1C=C(F)C=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 ONIWPUAJNWCHCD-UHFFFAOYSA-N 0.000 description 1
- MYJVQBFENXKLDD-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-(6-fluoropyridin-3-yl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=CC=1)C1=CC=C(F)N=C1 MYJVQBFENXKLDD-UHFFFAOYSA-N 0.000 description 1
- RJXINPONRPDCPP-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-[3-(trifluoromethoxy)phenyl]carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(OC(F)(F)F)C=CC=1)C1=CC=CC(F)=C1 RJXINPONRPDCPP-UHFFFAOYSA-N 0.000 description 1
- UMQLASXGJFGXFL-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=CC=1)C1=CC=CC=C1 UMQLASXGJFGXFL-UHFFFAOYSA-N 0.000 description 1
- IKJGVLHQJMBYIT-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-pyrazin-2-ylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1N=CC=NC=1)C1=CC=CC(F)=C1 IKJGVLHQJMBYIT-UHFFFAOYSA-N 0.000 description 1
- KFIPADWYPUOKNP-UHFFFAOYSA-N 2-[[4-[[(3-fluorophenyl)-pyridin-3-ylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=CC=1)C1=CC=CN=C1 KFIPADWYPUOKNP-UHFFFAOYSA-N 0.000 description 1
- RPNYUFBHLRPFJE-UHFFFAOYSA-N 2-[[4-[[(3-methoxyphenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound COC1=CC=CC(N(C(=O)OCC2CCC(COCC(O)=O)CC2)C=2C=CC=CC=2)=C1 RPNYUFBHLRPFJE-UHFFFAOYSA-N 0.000 description 1
- XEALUAITBGZBLD-UHFFFAOYSA-N 2-[[4-[[(3-methylphenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound CC1=CC=CC(N(C(=O)OCC2CCC(COCC(O)=O)CC2)C=2C=CC=CC=2)=C1 XEALUAITBGZBLD-UHFFFAOYSA-N 0.000 description 1
- IONAKCRDZACAPF-UHFFFAOYSA-N 2-[[4-[[(4-chloro-3-fluorophenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C(Cl)=CC=1)C1=CC=CC(F)=C1 IONAKCRDZACAPF-UHFFFAOYSA-N 0.000 description 1
- JPMFAXPZTPNMRF-UHFFFAOYSA-N 2-[[4-[[(4-chloro-3-fluorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C(Cl)=CC=1)C1=CC=CC=C1 JPMFAXPZTPNMRF-UHFFFAOYSA-N 0.000 description 1
- QORSZDIBAVDQHE-UHFFFAOYSA-N 2-[[4-[[(4-chlorophenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=CC=1)C1=CC=C(Cl)C=C1 QORSZDIBAVDQHE-UHFFFAOYSA-N 0.000 description 1
- WZVZYLAORQNPKG-UHFFFAOYSA-N 2-[[4-[[(4-chlorophenyl)-(4-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=CC(Cl)=CC=1)C1=CC=C(F)C=C1 WZVZYLAORQNPKG-UHFFFAOYSA-N 0.000 description 1
- ZCBHEQWCBIRSQH-UHFFFAOYSA-N 2-[[4-[[(4-ethoxyphenyl)-(3-fluorophenyl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(OCC)=CC=C1N(C=1C=C(F)C=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 ZCBHEQWCBIRSQH-UHFFFAOYSA-N 0.000 description 1
- WVZXMIGNODHKJW-UHFFFAOYSA-N 2-[[4-[[(4-fluorophenyl)-(5-methylthiophen-2-yl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound S1C(C)=CC=C1N(C=1C=CC(F)=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 WVZXMIGNODHKJW-UHFFFAOYSA-N 0.000 description 1
- JXNOKAGQNHMCNO-UHFFFAOYSA-N 2-[[4-[[(4-methoxyphenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N(C=1C=CC=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 JXNOKAGQNHMCNO-UHFFFAOYSA-N 0.000 description 1
- SULSUOLNIGMXAY-UHFFFAOYSA-N 2-[[4-[[(4-methylphenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(C)=CC=C1N(C=1C=CC=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 SULSUOLNIGMXAY-UHFFFAOYSA-N 0.000 description 1
- QVPMQWFOJCPFMV-UHFFFAOYSA-N 2-[[4-[[(5-methylthiophen-2-yl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound S1C(C)=CC=C1N(C=1C=CC=CC=1)C(=O)OCC1CCC(COCC(O)=O)CC1 QVPMQWFOJCPFMV-UHFFFAOYSA-N 0.000 description 1
- CHAJNUDWOFMFOR-UHFFFAOYSA-N 2-[[4-[[[(2,3-difluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C(=C(F)C=CC=1)F)C1=CC=CC=C1 CHAJNUDWOFMFOR-UHFFFAOYSA-N 0.000 description 1
- VRIPEANZOCQMDF-UHFFFAOYSA-N 2-[[4-[[[(2-fluoro-3-methoxyphenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound COC1=CC=CC(N(C(=O)NCC2CCC(COCC(O)=O)CC2)C=2C=CC=CC=2)=C1F VRIPEANZOCQMDF-UHFFFAOYSA-N 0.000 description 1
- UHOGOEXNXFENBI-UHFFFAOYSA-N 2-[[4-[[[(2-fluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C(=CC=CC=1)F)C1=CC=CC=C1 UHOGOEXNXFENBI-UHFFFAOYSA-N 0.000 description 1
- OQUIVMBUDKHEOP-UHFFFAOYSA-N 2-[[4-[[[(3,4-difluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(F)C(F)=CC=1)C1=CC=CC=C1 OQUIVMBUDKHEOP-UHFFFAOYSA-N 0.000 description 1
- VPMHZEHJPFKMPP-UHFFFAOYSA-N 2-[[4-[[[(3,5-difluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(F)C=C(F)C=1)C1=CC=CC=C1 VPMHZEHJPFKMPP-UHFFFAOYSA-N 0.000 description 1
- HGEWMZDYVDIXMG-UHFFFAOYSA-N 2-[[4-[[[(3-chloro-2-fluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C(=C(Cl)C=CC=1)F)C1=CC=CC=C1 HGEWMZDYVDIXMG-UHFFFAOYSA-N 0.000 description 1
- VPRUMPKRXZPRCY-UHFFFAOYSA-N 2-[[4-[[[(3-chloro-5-fluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(Cl)C=C(F)C=1)C1=CC=CC=C1 VPRUMPKRXZPRCY-UHFFFAOYSA-N 0.000 description 1
- FFCBKGGHZARAIH-UHFFFAOYSA-N 2-[[4-[[[(3-fluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(F)C=CC=1)C1=CC=CC=C1 FFCBKGGHZARAIH-UHFFFAOYSA-N 0.000 description 1
- ZPTXUMQKAFTPRD-UHFFFAOYSA-N 2-[[4-[[[(3-methoxyphenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound COC1=CC=CC(N(C(=O)NCC2CCC(COCC(O)=O)CC2)C=2C=CC=CC=2)=C1 ZPTXUMQKAFTPRD-UHFFFAOYSA-N 0.000 description 1
- NFUWQRGIGFGCMQ-UHFFFAOYSA-N 2-[[4-[[[(3-methylphenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound CC1=CC=CC(N(C(=O)NCC2CCC(COCC(O)=O)CC2)C=2C=CC=CC=2)=C1 NFUWQRGIGFGCMQ-UHFFFAOYSA-N 0.000 description 1
- UWOQFCDLJUCQRY-UHFFFAOYSA-N 2-[[4-[[[(4-chloro-3-fluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(F)C(Cl)=CC=1)C1=CC=CC=C1 UWOQFCDLJUCQRY-UHFFFAOYSA-N 0.000 description 1
- PZTAUECCXHDKAL-UHFFFAOYSA-N 2-[[4-[[[(4-chlorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PZTAUECCXHDKAL-UHFFFAOYSA-N 0.000 description 1
- KYSOHYJBELXHKF-UHFFFAOYSA-N 2-[[4-[[[(4-fluorophenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=CC(F)=CC=1)C1=CC=CC=C1 KYSOHYJBELXHKF-UHFFFAOYSA-N 0.000 description 1
- XSLBXRFHBBYNNI-UHFFFAOYSA-N 2-[[4-[[[(4-methoxy-2-methylphenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound CC1=CC(OC)=CC=C1N(C=1C=CC=CC=1)C(=O)NCC1CCC(COCC(O)=O)CC1 XSLBXRFHBBYNNI-UHFFFAOYSA-N 0.000 description 1
- QEPALHZQBXCAOJ-UHFFFAOYSA-N 2-[[4-[[[(4-methoxyphenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N(C=1C=CC=CC=1)C(=O)NCC1CCC(COCC(O)=O)CC1 QEPALHZQBXCAOJ-UHFFFAOYSA-N 0.000 description 1
- VCCLESWBUAEFDB-UHFFFAOYSA-N 2-[[4-[[[(4-methylphenyl)-phenylcarbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(C)=CC=C1N(C=1C=CC=CC=1)C(=O)NCC1CCC(COCC(O)=O)CC1 VCCLESWBUAEFDB-UHFFFAOYSA-N 0.000 description 1
- VOFVAIBNTPCAMB-UHFFFAOYSA-N 2-[[4-[[[benzhydryl(methyl)carbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(O)=O)CCC1CNC(=O)N(C)C(C=1C=CC=CC=1)C1=CC=CC=C1 VOFVAIBNTPCAMB-UHFFFAOYSA-N 0.000 description 1
- TXXGWNRPSVIVHP-UHFFFAOYSA-N 2-[[4-[[[phenyl-[3-(trifluoromethyl)phenyl]carbamoyl]amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1CNC(=O)N(C=1C=C(C=CC=1)C(F)(F)F)C1=CC=CC=C1 TXXGWNRPSVIVHP-UHFFFAOYSA-N 0.000 description 1
- WLCAXOYFRNFWEE-UHFFFAOYSA-N 2-[[4-[[bis(3-methylphenyl)carbamoylamino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound CC1=CC=CC(N(C(=O)NCC2CCC(COCC(O)=O)CC2)C=2C=C(C)C=CC=2)=C1 WLCAXOYFRNFWEE-UHFFFAOYSA-N 0.000 description 1
- RPJLXUCXXPIYHL-UHFFFAOYSA-N 2-[[4-[[bis(4-methylphenyl)carbamoylamino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C1=CC(C)=CC=C1N(C=1C=CC(C)=CC=1)C(=O)NCC1CCC(COCC(O)=O)CC1 RPJLXUCXXPIYHL-UHFFFAOYSA-N 0.000 description 1
- JVBFUYDFNLDSIO-UHFFFAOYSA-N 2-[[4-[[diphenylcarbamoyl(methyl)amino]methyl]cyclohexyl]methoxy]acetic acid Chemical compound C=1C=CC=CC=1N(C=1C=CC=CC=1)C(=O)N(C)CC1CCC(COCC(O)=O)CC1 JVBFUYDFNLDSIO-UHFFFAOYSA-N 0.000 description 1
- MJZLKZMMRNQZMR-UHFFFAOYSA-N 2-[[4-[[phenyl(pyridin-2-yl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1N=CC=CC=1)C1=CC=CC=C1 MJZLKZMMRNQZMR-UHFFFAOYSA-N 0.000 description 1
- QXAAUDQDZIGFKZ-UHFFFAOYSA-N 2-[[4-[[phenyl(pyridin-3-yl)carbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=NC=CC=1)C1=CC=CC=C1 QXAAUDQDZIGFKZ-UHFFFAOYSA-N 0.000 description 1
- AVSLRBPFOAJKLF-UHFFFAOYSA-N 2-[[4-[bis(3-fluorophenyl)carbamoyloxymethyl]cyclohexyl]methoxy]acetic acid Chemical compound C1CC(COCC(=O)O)CCC1COC(=O)N(C=1C=C(F)C=CC=1)C1=CC=CC(F)=C1 AVSLRBPFOAJKLF-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- XXPIPAHIUYOHGT-UHFFFAOYSA-N C(C)(C)O.[K].C(C)(=O)O Chemical compound C(C)(C)O.[K].C(C)(=O)O XXPIPAHIUYOHGT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 101000692650 Homo sapiens Prostacyclin receptor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000034906 Medical device complication Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- XCTTVNSXEHWZBI-UHFFFAOYSA-N n-(2-methylpropyl)formamide Chemical compound CC(C)CNC=O XCTTVNSXEHWZBI-UHFFFAOYSA-N 0.000 description 1
- NRMJMIGWXUCEEW-UHFFFAOYSA-N n-butan-2-ylformamide Chemical compound CCC(C)NC=O NRMJMIGWXUCEEW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006095 n-butyl sulfinyl group Chemical group 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- FJLHLDBEZKTSOK-UHFFFAOYSA-N n-ethyl-n-methylformamide Chemical compound CCN(C)C=O FJLHLDBEZKTSOK-UHFFFAOYSA-N 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- ZKTLKYRAZWGBDB-UHFFFAOYSA-N n-methyl-n-propan-2-ylformamide Chemical compound CC(C)N(C)C=O ZKTLKYRAZWGBDB-UHFFFAOYSA-N 0.000 description 1
- KVTGAKFJRLBHLU-UHFFFAOYSA-N n-propan-2-ylformamide Chemical compound CC(C)NC=O KVTGAKFJRLBHLU-UHFFFAOYSA-N 0.000 description 1
- 125000006093 n-propyl sulfinyl group Chemical group 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- KSQNMAKOXZCPLJ-UHFFFAOYSA-N tert-butyl 2-cyclohexyloxyacetate Chemical class CC(C)(C)OC(=O)COC1CCCCC1 KSQNMAKOXZCPLJ-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6985708P | 2008-03-18 | 2008-03-18 | |
| US61/069,857 | 2008-03-18 | ||
| US12362108P | 2008-04-09 | 2008-04-09 | |
| US61/123,621 | 2008-04-09 | ||
| US20722009P | 2009-02-09 | 2009-02-09 | |
| US61/207,220 | 2009-02-09 | ||
| US20945309P | 2009-03-06 | 2009-03-06 | |
| US61/209,453 | 2009-03-06 | ||
| PCT/US2009/001688 WO2009117095A1 (en) | 2008-03-18 | 2009-03-17 | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090229A Division JP2014210774A (ja) | 2008-03-18 | 2014-04-24 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011515396A JP2011515396A (ja) | 2011-05-19 |
| JP2011515396A5 true JP2011515396A5 (enExample) | 2014-04-17 |
| JP5536752B2 JP5536752B2 (ja) | 2014-07-02 |
Family
ID=40834524
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011500799A Active JP5536752B2 (ja) | 2008-03-18 | 2009-03-17 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2014090229A Withdrawn JP2014210774A (ja) | 2008-03-18 | 2014-04-24 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2015174518A Withdrawn JP2016028062A (ja) | 2008-03-18 | 2015-09-04 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2017225703A Withdrawn JP2018035194A (ja) | 2008-03-18 | 2017-11-24 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2019183730A Withdrawn JP2020097564A (ja) | 2008-03-18 | 2019-10-04 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2022000959A Pending JP2022050538A (ja) | 2008-03-18 | 2022-01-06 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2024002477A Pending JP2024028458A (ja) | 2008-03-18 | 2024-01-11 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090229A Withdrawn JP2014210774A (ja) | 2008-03-18 | 2014-04-24 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2015174518A Withdrawn JP2016028062A (ja) | 2008-03-18 | 2015-09-04 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2017225703A Withdrawn JP2018035194A (ja) | 2008-03-18 | 2017-11-24 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2019183730A Withdrawn JP2020097564A (ja) | 2008-03-18 | 2019-10-04 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2022000959A Pending JP2022050538A (ja) | 2008-03-18 | 2022-01-06 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
| JP2024002477A Pending JP2024028458A (ja) | 2008-03-18 | 2024-01-11 | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 |
Country Status (23)
| Country | Link |
|---|---|
| US (9) | US8895776B2 (enExample) |
| EP (3) | EP2280696B9 (enExample) |
| JP (7) | JP5536752B2 (enExample) |
| KR (13) | KR20200034831A (enExample) |
| CN (4) | CN103483226A (enExample) |
| AU (1) | AU2009226151B2 (enExample) |
| CA (1) | CA2728756C (enExample) |
| CO (1) | CO6321227A2 (enExample) |
| CY (1) | CY1115776T1 (enExample) |
| DK (1) | DK2280696T5 (enExample) |
| EA (1) | EA019882B1 (enExample) |
| ES (3) | ES2971909T3 (enExample) |
| HR (1) | HRP20141209T2 (enExample) |
| HU (1) | HUE023239T4 (enExample) |
| IL (1) | IL207873A0 (enExample) |
| MX (1) | MX2010010157A (enExample) |
| NZ (1) | NZ587693A (enExample) |
| PL (1) | PL2280696T3 (enExample) |
| PT (1) | PT2280696E (enExample) |
| RS (1) | RS53684B9 (enExample) |
| SI (1) | SI2280696T1 (enExample) |
| WO (1) | WO2009117095A1 (enExample) |
| ZA (1) | ZA201006694B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903324B (zh) | 2007-12-17 | 2013-07-03 | 联合治疗公司 | 一种制备Remodulin中的活性成分曲前列素的改良方法 |
| EP2280696B9 (en) * | 2008-03-18 | 2015-12-09 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| EP2367797A1 (en) | 2008-11-26 | 2011-09-28 | Arena Pharmaceuticals, Inc. | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| US8940891B2 (en) | 2008-12-08 | 2015-01-27 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| US20120225937A1 (en) * | 2009-09-23 | 2012-09-06 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pg12 receptor agonists |
| CN103261142B (zh) | 2010-06-03 | 2014-12-10 | 联合治疗公司 | 曲前列环素的制备 |
| US8461393B2 (en) | 2011-03-02 | 2013-06-11 | United Therapeutics Corporation | Synthesis of intermediate for treprostinil production |
| CA2951259A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| JP6224872B1 (ja) | 2014-10-20 | 2017-11-01 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリン誘導体を生成するための中間体の合成 |
| NZ731751A (en) | 2014-10-23 | 2023-07-28 | Arena Pharm Inc | Method of treating conditions related to the pgi2 receptor |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016073738A2 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| RU2632449C1 (ru) * | 2016-04-26 | 2017-10-04 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) | Способ оптимизации лечения мужчин кардиотропной терапией и заместительной гормональной терапией при андрогенодефиците с артериальной гипертензией |
| JP2019533713A (ja) * | 2016-11-10 | 2019-11-21 | アレーナ ファーマシューティカルズ，インク． | ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法 |
| CN110381951A (zh) | 2016-12-14 | 2019-10-25 | 瑞必治公司 | 用于治疗肺性高血压和其他肺病症的方法及组合物 |
| CN110582271B (zh) * | 2017-03-01 | 2022-06-14 | 阿瑞那制药公司 | 包含pgi2受体激动剂的组合物及其制备方法 |
| CA3070805A1 (en) * | 2017-07-27 | 2019-01-31 | Allergan, Inc. | Prostacyclin receptor agonists for reduction of body fat |
| WO2019032626A1 (en) | 2017-08-07 | 2019-02-14 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2019154363A1 (zh) | 2018-02-07 | 2019-08-15 | 南京明德新药研发有限公司 | 前列环素受体受体激动剂 |
| WO2019222764A1 (en) * | 2018-05-16 | 2019-11-21 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| CN112638865B (zh) * | 2018-09-06 | 2022-07-26 | 广东东阳光药业有限公司 | 药物共晶体及其制备方法 |
| CN110903219A (zh) * | 2018-09-18 | 2020-03-24 | 广东东阳光药业有限公司 | 酰胺衍生物的盐及其制备方法 |
| CN114213256B (zh) * | 2021-12-27 | 2025-03-25 | 维思普新材料（苏州）有限公司 | 一种二(4-联苯基)胺的制备方法 |
| AU2023222747A1 (en) * | 2022-02-15 | 2024-08-22 | United Therapeutics Corporation | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
| US20240002334A1 (en) * | 2022-03-17 | 2024-01-04 | United Therapeutics Corporation | Ralinepag prodrugs and uses thereof |
| WO2025193579A1 (en) | 2024-03-11 | 2025-09-18 | United Therapeutics Corporation | Methods of making ip-receptor agonists |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2945530A1 (de) * | 1979-11-10 | 1981-06-04 | Chemische Werke Hüls AG, 4370 Marl | Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide |
| JPS5686417A (en) * | 1979-12-17 | 1981-07-14 | Nissan Motor | Contact discriminating circuit |
| JPH03160438A (ja) | 1989-11-20 | 1991-07-10 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| CA2036192A1 (en) | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
| CA2085844A1 (en) | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
| JPH06329598A (ja) | 1993-05-19 | 1994-11-29 | Daicel Chem Ind Ltd | エステルの製造方法 |
| DE4318889A1 (de) | 1993-06-07 | 1994-12-08 | Bayer Ag | Verfahren zur Herstellung von organischen Carbamaten |
| JP3160438B2 (ja) | 1993-09-29 | 2001-04-25 | 株式会社東芝 | 交通流予測装置 |
| JP3245864B2 (ja) | 1994-03-10 | 2002-01-15 | 藤沢薬品工業株式会社 | プロスタグランジンｉ２アゴニストとしてのナフタレン誘導体 |
| JPH11269138A (ja) | 1998-03-20 | 1999-10-05 | Mitsubishi Paper Mills Ltd | 有機塩基発生剤 |
| US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| PL207869B1 (pl) * | 2000-03-16 | 2011-02-28 | Hoffmann La Roche | Pochodne kwasu karboksylowego, środek farmaceutyczny i sposób wytwarzania pochodnych kwasu karboksylowego |
| WO2002055484A1 (en) | 2001-01-12 | 2002-07-18 | Takeda Chemical Industries, Ltd. | Biaryl compound, process for producing the same, and agent |
| AU2002240235B2 (en) * | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| TWI316055B (enExample) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| PL368129A1 (en) | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TWI293715B (en) | 2002-10-10 | 2008-02-21 | Sipix Imaging Inc | A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display |
| CN1735598A (zh) * | 2002-11-11 | 2006-02-15 | 拜耳医药保健股份公司 | 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物 |
| MXPA05008450A (es) | 2003-02-10 | 2005-10-18 | Vertex Pharma | Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos. |
| GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
| AU2004274155A1 (en) * | 2003-09-22 | 2005-03-31 | F. Hoffmann-La Roche Ag | Aminoalkylamide substituted cyclohexyl derivatives |
| JP4402413B2 (ja) | 2003-09-29 | 2010-01-20 | 財団法人２１あおもり産業総合支援センター | Ｕ字型化合物およびこれを含む液晶組成物 |
| DE102004006785A1 (de) | 2004-02-11 | 2005-09-08 | Mayr, Herbert, Prof. Dr. | Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure |
| CA2576971A1 (en) | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| JP2006083085A (ja) | 2004-09-15 | 2006-03-30 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体の製造法およびその合成中間体 |
| JP4792731B2 (ja) | 2004-11-12 | 2011-10-12 | Ｄｉｃ株式会社 | 重合性液晶組成物及び当該組成物の硬化物 |
| WO2007051255A1 (en) | 2005-11-04 | 2007-05-10 | The University Of Sydney | Process for the preparation of compounds containing an azacyclic ring system |
| JP2007161867A (ja) | 2005-12-14 | 2007-06-28 | Toyo Ink Mfg Co Ltd | インキ組成物 |
| US7687481B2 (en) * | 2006-03-10 | 2010-03-30 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| BRPI0713096A2 (pt) | 2006-05-09 | 2012-10-16 | Hemaquest Pharmaceuticals Inc | métodos para tratar distúrbios sangüìneos |
| EP2280696B9 (en) * | 2008-03-18 | 2015-12-09 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| EP2367797A1 (en) | 2008-11-26 | 2011-09-28 | Arena Pharmaceuticals, Inc. | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| US8940891B2 (en) | 2008-12-08 | 2015-01-27 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| US20120225937A1 (en) | 2009-09-23 | 2012-09-06 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pg12 receptor agonists |
| JP3160438U (ja) | 2010-04-14 | 2010-06-24 | 孝枝 袴田 | 弦楽器演奏練習補助具 |
-
2009
- 2009-03-17 EP EP09721284.9A patent/EP2280696B9/en active Active
- 2009-03-17 KR KR1020207008358A patent/KR20200034831A/ko not_active Withdrawn
- 2009-03-17 KR KR1020167029281A patent/KR20160124925A/ko not_active Withdrawn
- 2009-03-17 KR KR1020247003821A patent/KR20240024285A/ko not_active Withdrawn
- 2009-03-17 CA CA2728756A patent/CA2728756C/en active Active
- 2009-03-17 ES ES21156716T patent/ES2971909T3/es active Active
- 2009-03-17 KR KR1020227034651A patent/KR20220143141A/ko not_active Withdrawn
- 2009-03-17 WO PCT/US2009/001688 patent/WO2009117095A1/en not_active Ceased
- 2009-03-17 KR KR1020227006477A patent/KR20220031743A/ko not_active Withdrawn
- 2009-03-17 KR KR1020207032009A patent/KR20200129175A/ko not_active Withdrawn
- 2009-03-17 KR KR1020107023119A patent/KR101670089B1/ko active Active
- 2009-03-17 EP EP14182803.8A patent/EP2857015B1/en active Active
- 2009-03-17 KR KR1020237018422A patent/KR20230085944A/ko not_active Ceased
- 2009-03-17 JP JP2011500799A patent/JP5536752B2/ja active Active
- 2009-03-17 HR HRP20141209TT patent/HRP20141209T2/hr unknown
- 2009-03-17 PL PL09721284T patent/PL2280696T3/pl unknown
- 2009-03-17 KR KR1020197016593A patent/KR20190067947A/ko not_active Withdrawn
- 2009-03-17 EA EA201071090A patent/EA019882B1/ru unknown
- 2009-03-17 KR KR1020187006345A patent/KR20180027644A/ko not_active Withdrawn
- 2009-03-17 CN CN201310322766.7A patent/CN103483226A/zh active Pending
- 2009-03-17 MX MX2010010157A patent/MX2010010157A/es active IP Right Grant
- 2009-03-17 SI SI200931060T patent/SI2280696T1/sl unknown
- 2009-03-17 HU HUE09721284A patent/HUE023239T4/en unknown
- 2009-03-17 KR KR1020247036522A patent/KR20240163755A/ko not_active Ceased
- 2009-03-17 US US12/933,196 patent/US8895776B2/en active Active
- 2009-03-17 ES ES14182803T patent/ES2875944T3/es active Active
- 2009-03-17 PT PT97212849T patent/PT2280696E/pt unknown
- 2009-03-17 EP EP21156716.9A patent/EP3884934B1/en active Active
- 2009-03-17 DK DK09721284.9T patent/DK2280696T5/en active
- 2009-03-17 AU AU2009226151A patent/AU2009226151B2/en active Active
- 2009-03-17 RS RS20140679A patent/RS53684B9/sr unknown
- 2009-03-17 KR KR1020187030653A patent/KR20180118256A/ko not_active Withdrawn
- 2009-03-17 NZ NZ587693A patent/NZ587693A/en unknown
- 2009-03-17 KR KR1020217020737A patent/KR20210088008A/ko not_active Withdrawn
- 2009-03-17 CN CN200980117998.0A patent/CN102036659B/zh active Active
- 2009-03-17 ES ES09721284.9T patent/ES2525244T3/es active Active
- 2009-03-17 CN CN201410403124.4A patent/CN104262267B9/zh active Active
- 2009-03-17 CN CN201910053167.7A patent/CN110003123B/zh active Active
-
2010
- 2010-08-30 IL IL207873A patent/IL207873A0/en active IP Right Grant
- 2010-09-17 ZA ZA2010/06694A patent/ZA201006694B/en unknown
- 2010-10-07 CO CO10124941A patent/CO6321227A2/es active IP Right Grant
-
2012
- 2012-09-13 US US13/614,326 patent/US20130217706A1/en not_active Abandoned
-
2014
- 2014-04-24 JP JP2014090229A patent/JP2014210774A/ja not_active Withdrawn
- 2014-10-09 US US14/510,669 patent/US20150126527A1/en not_active Abandoned
- 2014-11-26 CY CY20141100986T patent/CY1115776T1/el unknown
-
2015
- 2015-09-04 JP JP2015174518A patent/JP2016028062A/ja not_active Withdrawn
-
2017
- 2017-03-02 US US15/447,573 patent/US10668033B2/en not_active Ceased
- 2017-11-24 JP JP2017225703A patent/JP2018035194A/ja not_active Withdrawn
-
2019
- 2019-10-04 JP JP2019183730A patent/JP2020097564A/ja not_active Withdrawn
-
2020
- 2020-04-14 US US16/848,746 patent/US20200375930A1/en not_active Abandoned
-
2022
- 2022-01-06 JP JP2022000959A patent/JP2022050538A/ja active Pending
- 2022-05-18 US US17/747,917 patent/USRE50267E1/en active Active
- 2022-06-07 US US17/834,293 patent/US20230121825A1/en not_active Abandoned
-
2023
- 2023-04-28 US US18/309,671 patent/US20230404954A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002477A patent/JP2024028458A/ja active Pending
- 2024-02-14 US US18/441,209 patent/US20250009693A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5536752B2 (ja) | プロスタサイクリン（ｐｇｉ２）受容体に関連する障害の処置に有用なｐｇｉ２受容体の調節因子 | |
| JP2011515396A5 (enExample) | ||
| HK40058729B (en) | Pharmaceutical composition comprising: 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid | |
| HK40058729A (en) | Pharmaceutical composition comprising: 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid | |
| HK1204278B (en) | Modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto | |
| HK1154206B (en) | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto | |
| KR20250175010A (ko) | 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 | |
| BRPI0910391B1 (pt) | Compostos moduladores do receptor de prostaciclina (pgi2) e os sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica os compreendendo, seus usos e processo para a preparação de uma composição |